

## ORIGINAL ARTICLE

# Association of interferon $\gamma$ T<sup>+874</sup>A and interleukin 12 p40 promoter CTCTAA/GC polymorphism with the need for respiratory support and perinatal complications in low birthweight neonates

G Bokodi, L Derzbach, I Bányász, T Tulassay, B Vásárhelyi

*Arch Dis Child Fetal Neonatal Ed* 2007;92:F25-F29. doi: 10.1136/adc.2005.086421

**Background:** Data support the role of interferon (IFN) $\gamma$  and interleukin (IL)12 in perinatal complications. IFN $\gamma$  T<sup>+874</sup>A and IL12 p40 promoter CTCTAA/GC polymorphisms may have an effect on cytokine production.

**Methods:** DNA was extracted from dried blood samples of 153 low birthweight (LBW) infants and 172 healthy term infants. IFN $\gamma$  and IL12 genetic polymorphisms were determined to investigate the association between polymorphisms and ventilation characteristics, bronchopulmonary dysplasia (BPD) and other perinatal disorders.

**Results:** The IFN $\gamma$  T<sup>+874</sup>A allele was over-represented in LBW infants. Carriers of the IFN $\gamma$  T<sup>+874</sup>T allele required mechanical ventilation and oxygen supplementation for time periods 41% and 35%, respectively, shorter than those required by those not carrying the IFN $\gamma$  T<sup>+874</sup>T allele. Stepwise logistic regression analysis showed that carriers of the IFN $\gamma$  T<sup>+874</sup>T allele were protected against BPD (odds ratio (OR) 0.35 (95% confidence interval (CI) (0.12 to 0.99))) and patent ductus arteriosus (OR 0.43 (95% CI 0.19 to 0.97)), whereas carriers of the IFN $\gamma$  T<sup>+874</sup>A allele were at higher risk of severe hypotension (OR 3.40 (95% CI 1.01 to 11.52)) and respiratory distress syndrome (OR 4.03 (95% CI 1.30 to 12.50)). Carriers of the IL12 GC allele were protected against pneumonia (OR 0.32 (95% CI 0.14 to 0.75)). Carriers of the IL12 CTCTAA allele were at higher risk of developing necrotising enterocolitis (NEC; OR 2.37 (95% CI 1.01 to 5.53)).

**Conclusions:** Carrier state of the IFN $\gamma$  T<sup>+874</sup>A allele presents an increased risk for premature birth and lung damage, as well as other perinatal complications. The risks of pneumonia and NEC are higher in heterozygotic carriers of the IL12 CTCTAA/GC polymorphism. Further studies are needed to determine whether these associations are the result of altered cytokine-producing capacity in infants carrying the tested alleles.

See end of article for authors' affiliations

Correspondence to:  
G Bokodi, First Department of Pediatrics, Semmelweis University Budapest, Bókyay u 53 H-1083, Hungary; bokodi@gyer1.sote.hu

Accepted 29 May 2006  
Published Online First 5 June 2006

Respiratory dysfunction, clinically characterised by the need for oxygen supplementation, is a common complication in preterm infants and is usually caused by perinatal lung damage. Risk factors contributing to lung damage include inadequate immune response triggered by various stimuli, such as infection and medical intervention, causing postnatal oxygen toxicity, mechanical injury, barotrauma and overextension.<sup>1-3</sup> These factors also contribute to other perinatal complications that increase the need for mechanical ventilation in newborns.<sup>4</sup>

Both innate and adaptive immunity are immature in preterm infants. Innate responses are non-specific reactions to microbes and exogenous stimuli, whereas adaptive responses are specific to the type of microbe or stimulus. The immaturity of the immune system has been linked to the unbalanced activation of immune cells, which results in damage of susceptible organs such as the lungs.<sup>3-8</sup> The effector cells of immunity (lymphocytes, natural killer cells, macrophages and neutrophil granulocytes) have a central role in this process. These cells communicate with each other through several cytokines, including tumour necrosis factor (TNF) $\alpha$ , interleukin (IL)1, IL4, IL6, IL8, IL10, IL12 and interferon (IFN) $\gamma$ .<sup>4 9-11</sup>

The production of cytokines is determined by inflammation, developmental factors and, to some extent, by genetic polymorphisms (single-nucleotide polymorphisms (SNPs)).<sup>12-17</sup> We and others have extensively investigated the association of some cytokine SNPs, such as TNF $\alpha$  G<sup>-308</sup>A variations, with preterm birth and perinatal disorders. Data have linked the carrier state of the TNF $\alpha$  G<sup>-308</sup>A allele to preterm birth,

intraventricular haemorrhage (IVH) and bronchopulmonary dysplasia (BPD).<sup>18-21</sup> Recently, we found that carriers of the TNF $\alpha$  G<sup>-308</sup>A allele are at increased risk for longer ventilator support.<sup>22</sup>

Most of these studies focus on cytokines implicated in adaptive immune response. Data on the importance of SNPs of other genes encoding cytokines of innate immunity in perinatal disorders are much more limited. IFN $\gamma$  and IL12 have a major role in the communication between macrophages and natural killer cells. IFN $\gamma$  is the principal macrophage-activating cytokine, but it also stimulates neutrophils and natural killer cells.<sup>10</sup> IL12 is a disulphide-linked heterodimer consisting of two subunits (p35 and p40). Many cells seem to synthesise the p35 subunit, but only activated mononuclear phagocytes and dendritic cells produce the p40 component and, consequently, the biologically active cytokine. IL12 stimulates IFN $\gamma$  production and the differentiation of Th1 cells, and improves the cytolytic functions of activated natural killer cells and CD8+ T lymphocytes.<sup>11</sup>

Genes encoding IL12 and IFN $\gamma$  have several functional SNPs; of these, the most widely investigated SNPs are the IL12 p40

**Abbreviations:** BPD, bronchopulmonary dysplasia; IFN, interferon; IVH, intraventricular haemorrhage; IRDS, idiopathic respiratory distress syndrome; LBW, low birthweight; NEC, necrotising enterocolitis; PCR, polymerase chain reaction; PDA, patent ductus arteriosus; RFLP, restriction fragment length polymorphism; SNP, single-nucleotide polymorphism; TNF, tumour necrosis factor

promoter GC/CTCTAA and IFN $\gamma$ T<sup>+874</sup>A.<sup>13 15 23</sup> We hypothesised that the carrier state of these SNPs influences the risk of some perinatal complications that may increase the need for ventilator support and also increase the risk for BPD. We tested this hypothesis in a heterogeneous population of very LBW infants.

## PATIENTS AND METHODS

### Patients

In our retrospective study, we analysed the medical records of consecutive LBW infants (birth weight  $\leq$  1500 g) and healthy term neonates who had been born and treated at the Second Department of Gynecology and Obstetrics, Semmelweis University, Budapest, Hungary, between 2000 and 2003. At the beginning of treatment in the neonatal intensive care unit or nursery ward, informed consent of parents was obtained to collect dried blood samples from their infants for scientific purposes. Blood samples were taken on the fifth day of life or after the beginning of oral feeding. Dried blood samples were stored at the phenylketonuria (PKU) screening laboratory and were sent for genotyping. In our study, we did not enrol those infants (1) whose parents refused to participate in scientific projects (2% of LBW and 5% of term neonates), (2) who died before collection of dried blood samples (12% of LBW infants) or (3) who died before discharge to home or nursery ward (6% of LBW infants). The total drop-out rates of LBW and term infants were 19% and 5%, respectively. Finally, we enrolled 172 healthy term neonates (87 boys and 85 girls, median birth weight 3400 (range 2700–4200) g; median gestational age 40 (range 37–42) weeks; prevalence of intrauterine retardation (defined as gestational age-matched birth weight <10th centile) 0.03; and no reported perinatal complication) and 153 LBW neonates (76 boys and 77 girls, median birth weight 1180 (range 510–1500) g, median gestational age 29 (range 24–36) weeks; prevalence of intrauterine retardation 0.18). For LBW infants, we recorded the median duration of mechanical ventilation (4 (range 0–60) days) and length of total oxygen supplementation (12 (range 0–80) days), and the presence of BPD ( $n=27$ ). BPD was defined as oxygen dependency at 28 days' postnatal age or at 36 weeks' postmenstrual age.<sup>24</sup> Prenatally, 51 infants were treated with steroid; postnatally, 44 infants were treated with dobutamine and 23 with surfactant. Eleven underwent surgical intervention. Perinatal complications in the medical histories were recorded, such as pneumonia ( $n=36$ ), necrotising enterocolitis (NEC;  $n=52$ ), sepsis ( $n=47$ ), acute renal failure ( $n=40$ ), severe hypotension in infection ( $n=49$ ), idiopathic respiratory distress syndrome (IRDS;  $n=80$ ), patent ductus arteriosus (PDA;  $n=50$ ) and IVH ( $n=47$ ). We defined these complications according to internationally accepted criteria.<sup>25 26</sup>

### Samples

DNA was extracted using an agent (Chelex, BioRad, Germany) according to the manufacturer's instructions. The institutional ethics committee approved the study (TUKÉB 14/2003).

### Genotyping

Genotyping was carried out with polymerase chain reaction (PCR) and, subsequently, with restriction fragment length polymorphism (RFLP) methods (table 1).

PCR amplifications were carried out in a buffer of final volume 50  $\mu$ l, consisting of 25 pmol of each primer, 0.2 mmol/l of each deoxyribonucleotide triphosphate, 2.0 mmol/l magnesium chloride (MgCl<sub>2</sub>) and 0.3 U *Taq* polymerase (Invitrogen, Carlsbad, California, USA). RFLP was carried out in a PCR product of volume 15  $\mu$ l. The PCR and RFLP products were separated on 2.5% agarose gels (Invitrogen, Carlsbad,

California, USA) and visualised under UV illumination, stained with 0.4 mg/l ethidium bromide (Amersham Pharmacia Biotech, Uppsala, Sweden).

### Statistical analysis

Hardy–Weinberg equilibrium was calculated to evaluate the relationship between measured and expected genotype frequencies. Categorical data were analysed using the  $\chi^2$  test. The number of days on oxygen supplementation and mechanical ventilation were log transformed. We applied multiple linear regression analysis to test the effect of genotypes on ventilation characteristics. We used stepwise binary logistic regression to determine the independent association between BPD and polymorphisms. These associations were adjusted for gestational age and clinical characteristics. We also tested the association of the genotypes with perinatal complications other than BPD; for this purpose, we also used a stepwise binary logistic regression approach. The level of significance was set at  $p<0.05$ . All calculations were carried out with the statistical software package SPSS V.10.0.

## RESULTS

The distribution of the investigated genotypes fulfilled Hardy–Weinberg criteria in each population studied. The prevalence of IFN $\gamma$  T<sup>+874</sup>A genotypes (TT/TA/AA) in term and LBW infants was 0.33/0.46/0.21 and 0.17/0.56/0.25, respectively, with a significantly higher prevalence of the IFN $\gamma$ <sup>+874</sup>A allele among LBW infants (0.44  $\nu$  0.54, odds ratio (OR) 1.50, 95% confidence interval (95% CI) 1.10 to 2.05). The prevalence of IL12 p40 promoter CTCTAA/GC (I/D) genotypes (II/ID/DD) in term and LBW infants was 0.33/0.47/0.20 and 0.28/0.50/0.20, respectively, with similar prevalence in both groups (0.44  $\nu$  0.46).

In our stepwise linear regression model, the need for ventilator support was associated with gestational age at birth, and the presence of IVH and IFN $\gamma$ <sup>+874</sup>T genotype; carriers of the IFN $\gamma$ <sup>+874</sup>T allele required mechanical ventilation and oxygen supplementation for time periods 41% and 35%, respectively, shorter than that required by infants with IFN $\gamma$ <sup>+874</sup>AA genotype (table 2). The IL12 polymorphism showed no association with ventilation characteristics.

We also analysed the association between genotypes and perinatal complications. The  $\chi^2$  test showed that the distribution of IL12 genotypes (II/ID/DD) is different only in LBW infants with and without pneumonia (0.23/0.57/0.20  $\nu$  0.47/0.36/0.17, OR 1.76, 95% CI 1.13 to 2.76,  $p=0.014$ , respectively). The stepwise binary logistic regression analysis, however, showed that the carrier state of the IFN $\gamma$ <sup>+874</sup>T allele is an independent determinant of BPD (OR 0.35, 95% CI 0.12 to 0.99). The IL12 polymorphism by itself was not associated with risk for BPD; however, we found an increased risk for pneumonia in carriers of the IL12 CTCTAA allele (OR 1.76, 95% CI 1.13 to 2.76). Binary logistic regression analysis also showed an association between the IFN $\gamma$  A<sup>+874</sup>T genotype and several perinatal complications that increase the need for ventilator support. We found that carriers of the IFN $\gamma$ <sup>+874</sup>T allele were protected against PDA (table 2 shows corresponding ORs), and carriers of the IFN $\gamma$ <sup>+874</sup>A allele were at higher risk for severe hypotension and IRDS. These associations were adjusted for gestational age and other risk factors.

For the IL12 p40 promoter CTCTAA/GC polymorphism, we found that carriers of the IL12 GC allele were at lower risk for pneumonia, and carriers of the IL12 CTCTAA allele were at higher risk for NEC. Heterozygosity was associated with a decreased risk for pneumonia and an increased risk for NEC compared with homozygotes for the tested IL12 polymorphism.

We also tested for an association between the common carrier state of the IFN $\gamma$ <sup>+874</sup>A $\times$ IL12 GC alleles and perinatal

**Table 1** Conditions for polymerase chain reaction and restriction fragment length polymorphism

	IFN $\gamma$ T <sup>+874</sup> A polymorphism	IL12 GC/CTCTAA polymorphism
Forward primer	5'-TTC TTA CAA CAC AAA ATC AAG TC-3'	5'-TGT TCT AAT GTG GGG GCC ACG-3'
Reverse primer	5'-AGT ATT CCC AAA AGG CIT ATC T-3'	5'-CTG ITT GTC AGC AGA CCT TCC T-3'
Denaturation temperature (20 s)	94°C	94°C
Annealing temperature (20 s)	50°C	55°C
Extension temperature (30 s)	72°C	72°C
Restriction enzyme	8 U of <i>Alw26</i> *	10 U of <i>Tai</i> I*
Overnight restriction, temperature	37°C	65°C
Product size	340/26 bp A allele 366 bp T allele	205/22 bp CTCTAA allele 223 bp GC allele

IFN, interferon; IL, interleukin

\* Provided by New England Biolabs, Beverly, Madison, USA

complications. We found that infants simultaneously carrying the IFN $\gamma$ <sup>+874</sup>A and IL12 GC alleles were at increased risk for severe hypotension with infection.

### Multiple linear regression analysis

The duration of mechanical ventilation and oxygen supplementation in days was log transformed to achieve normal distribution. The parameters were adjusted for gestational age and perinatal complication possibly affecting ventilation characteristics. Gestational age was also a significant ( $p < 0.001$ ) predictor. B is the raw regression coefficient;  $e^B$  is the ratio of the durations of ventilation to oxygen supplementation between infants with and without IFN T allele.

### Stepwise binary logistic regression

The association between genotype and perinatal complications was adjusted for gestational age and known risk factors. Gestational age was a significant ( $p < 0.05$ ) predictor of each dependent variable; IVH was a significant ( $p < 0.01$ ) predictor of ventilation durations and BPD; severe hypotension was a significant ( $p < 0.05$ ) predictor of pneumonia; and IRDS was a significant ( $p < 0.05$ ) predictor of severe hypotension in infection.  $\beta$  is the standardised regression coefficient.

## DISCUSSION

The lungs are some of the most susceptible organs during the perinatal period. Clinical experience supports that prematurity itself along with several perinatal complications may trigger lung damage that is clinically characterised by increased need for ventilator support. Studies have shown that an exaggerated

production of inflammatory cytokines increases the risk for chronic mechanical ventilation and BPD.<sup>1 4 21 27</sup>

In this study, we tested the association of functional SNPs of two inflammatory cytokines IFN $\gamma$  and IL12 with the length of postnatal oxygen requirement and risk for BPD and other perinatal disorders. Although the observed distributions of the IFN $\gamma$  and IL12 genetic polymorphisms in healthy newborns are similar to reference values reported in other populations, the IFN $\gamma$ <sup>+874</sup>A allele occurred more frequently in LBW infants.<sup>14 28</sup> This finding implies that IFN $\gamma$  is associated with the pathogenesis of preterm birth. Indeed, recent data collected in women also suggest that the maternal carrier state of this SNP may contribute to recurrent pregnancy loss and, possibly, to premature birth.<sup>29 30</sup> However, we tested only infants' genotypes and had no data about the mothers. As half of the alleles in the offspring originate from the mother, we can only speculate whether this association is attributable to the infant's genotype or is the result of the mother's genotype. Therefore, further studies on the simultaneous genotyping of parents and offspring should be conducted to determine the role of the IFN $\gamma$ T<sup>+874</sup>A SNP in preterm birth.

On testing the association between genotype and ventilation characteristics of infants, we found that carriers of the IFN $\gamma$ <sup>+874</sup>T allele required mechanical ventilation and oxygen supplementation for a time period about 40% shorter than that required by infants without this allele. As the presence of the IFN $\gamma$ <sup>+874</sup>T allele is linked to increased IFN $\gamma$  levels, it is tempting to speculate that our results are due to altered IFN $\gamma$  levels.<sup>13</sup> Newborn infants with low in vitro production of IFN $\gamma$  were at higher risk for longer mechanical ventilation in the presence of respiratory syncytial virus infection.<sup>31</sup>

**Table 2** Association of the investigated genotypes with ventilation characteristics and perinatal complications

Results of multiple linear regression analysis				
Dependent variable	Independent variables	p	B	$e^B$
Log (duration of mechanical ventilation)	Carrier state of the IFN T allele	0.002	-0.533	0.59
Log (duration of oxygen supplementation)	Carrier state of the IFN T allele	0.003	-0.438	0.65
Results of stepwise binary logistic regression analysis				
Dependent variable	Independent variables	p	$\beta$	$e^{\beta}$ = OR, 95% CI
Bronchopulmonary dysplasia	IFN T allele	0.049	-1.054	0.35, 0.12 to 0.99
	IFN AA $\times$ IL12 ID genotype	0.042	1.488	4.43, 1.06 to 18.6
Patent ductus arteriosus	IFN T allele	0.043	-0.837	0.43, 0.19 to 0.97
	IFN A allele	0.016	1.395	4.03, 1.30 to 12.5
Idiopathic respiratory distress syndrome	IFN A allele	0.049	1.225	3.40, 1.01 to 11.5
	IL12 D allele	0.009	-1.135	0.322, 0.138 to 0.750
Severe hypotension in infection	IL12 DI genotype	0.016	-1.076	0.341, 0.142 to 0.819
	IL12 I allele	0.046	0.862	2.369, 1.013 to 5.533
Pneumonia	IL12 DI genotype	0.004	1.069	2.914, 1.410 to 6.015
	IL12 I allele	0.004	1.069	2.914, 1.410 to 6.015

$\beta$ , standardised regression coefficient; B, raw regression coefficient;  $e^B$ , ratio of the durations of ventilation to oxygen supplementation between infants with and without IFN T allele; IFN, interferon; IL, interleukin.

### What is already known on this topic

- Inflammatory cytokines (tumour necrosis factor  $\alpha$ , interleukin (IL)1 $\beta$ , IL8, etc) play a key part in the pathomechanism of perinatal complications including bronchopulmonary dysplasia.
- Interferon  $\gamma$  and IL12 are the most important inflammatory cytokines of innate immunity.
- Cytokine levels could be affected by certain genetic polymorphisms.

Although no data are available on the association between BPD and altered IL12 and IFN $\gamma$  levels, our finding that the IFN $\gamma^{+874T}$  allele is protective, whereas the simultaneous presence of IFN $\gamma^{+874A}$  and IL12 GC/CTCTAA genotype is a risk factor for BPD, is in line with the current theories about the implication of disturbed cytokine network in BPD.<sup>3-4</sup> Increased levels of other inflammatory cytokines, such as IL1 $\beta$ , TNF $\alpha$  and IL8, have a key role in the pathomechanism of lung damage and BPD.<sup>4 21 22 24 27</sup> These cytokines also play a part in the regulation of IL12 and IFN $\gamma$  production; therefore, it is reasonable to postulate that IL12 and IFN $\gamma$  also contribute to BPD.<sup>32</sup> The association between IFN $\gamma$  and IL12 genotypes with BPD would support this hypothesis.

The need for mechanical ventilation and oxygen supplementation is influenced by several perinatal complications.<sup>1-4 25 33 34</sup> We therefore also examined the independent association of the IL12 promoter GC/CTCTAA and IFN $\gamma^{+874A}$  genetic polymorphisms with NEC, pneumonia, infection and sepsis, because inflammation plays a key part in the pathomechanism of all four perinatal complications.<sup>25</sup> Although we found no association between sepsis and the tested genotypes, we observed that alleles with low IFN $\gamma$  levels increase the risk for hypotension in patients with sepsis. We also found that patients with inherited susceptibility for low IL12 levels (ie, those with the IL12 promoter CTCTAA allele) are at increased risk for NEC and pneumonia. The causative role of these genetic variants in these perinatal complications should be verified with serial determinations of IL12 and IFN $\gamma$  levels.

We also showed that patients who are predisposed to low IFN $\gamma$  levels are at increased risk for PDA. No data on animals and humans are available about the possible implication of IFN $\gamma$  in PDA; further studies should be carried out to elucidate this issue. We also found that infants with low IFN $\gamma$  levels are at increased risk for IRDS. Although the main risk factor for IRDS is immaturity, inflammatory cytokines such as IL1 $\beta$  and TNF $\alpha$  do affect lung development and protect against IRDS.<sup>35 36</sup> Our results raise the possibility that IFN $\gamma$  genotype may influence the infant's risk for IRDS through its effect on inflammatory cytokine levels. Again, this speculation needs experimental verification.

Our study has limitations. The estimated drop-out rate of LBW infants in our study was approximately 20%, which may be a selection bias. However, genotype distributions fulfilled the Hardy-Weinberg criteria in each population tested, which suggests that the investigated genotypes did not have a major effect on perinatal mortality. The lack of cytokine levels is another limitation; serial testing along with genotyping may disclose a causative role among the investigated SNPs, cytokine levels and perinatal morbidity. Furthermore, it should also be considered that cytokines do not act in an isolated manner; rather, they exert their effect in a complex network. The SNPs of other cytokines have been tested in several studies on newborns. Most of the data concern the association of perinatal morbidity with TNF $\alpha$  SNPs.<sup>18-22</sup> Probably, it would be of interest

### What this study adds

- This study suggests an association between perinatal complications, including bronchopulmonary dysplasia, and the carrier state of interferon  $\gamma$  T<sup>+874</sup>A and interleukin (IL)12 p40 promoter CTCTAA/GC polymorphisms.

to test the interaction among TNF $\alpha$ , IL12 and IFN $\gamma$  genotypes in a larger cohort of preterm infants.

In summary, our results suggest several associations between perinatal morbidity and the IFN $\gamma$  and IL12 SNPs. Although the change in cytokine-producing capacity is an attractive hypothesis for our results, the causative role of these SNPs should be investigated in further studies.

### Authors' affiliations

**G Bokodi, L Derzbach, I Bányász**, First Department of Pediatrics, Semmelweis University, Budapest, Hungary

**T Tulassay, B Vásárhelyi**, Research Group of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary

Funding: This study was financially supported by OTKA Grant T046056 and GVOP-3-1-1/2004-300.

Competing interests: None.

### REFERENCES

- 1 Bourbon J, Boucherat O, Chailley-Heu B, et al. Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. *Pediatr Res* 2005;**57**:R38-46.
- 2 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;**163**:1723-9.
- 3 Speer CP. Inflammation and bronchopulmonary dysplasia. *Semin Neonatal* 2003;**8**:29-38.
- 4 De Dooy JJ, Mahieu LM, Van Bever HP. The role of inflammation in the development of chronic lung disease in neonates. *Eur J Pediatr* 2001;**160**:457-63.
- 5 Gasparoni A, Ciardelli L, Avanzini A, et al. Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults. *Biol Neonate* 2003;**84**:297-303.
- 6 Jones CA, Warner JO. Regulating a regulator: IFN $\gamma$  production by the neonate. *Clin Exp Allergy* 1999;**29**:865-8.
- 7 Marodi L. IL-12 and IFN- $\gamma$  deficiencies in human neonates. *Pediatr Res* 2001;**49**:316.
- 8 Marodi L. Down-regulation of T<sub>H1</sub> responses in human neonates. *Clin Exp Immunol* 2002;**128**:1-2.
- 9 Gessani S, Belardelli F. IFN- $\gamma$  expression in macrophages and its possible biological significance. *Cytokine Growth Factor Rev* 1998;**9**:117-23.
- 10 Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. *Immunol Rev* 2004;**202**:8-32.
- 11 Waitford WT, Moriguchi M, Morinobu A, et al. The biology of IL-12: coordinating innate and adaptive immune responses. *Cytokine Growth Factor Rev* 2003;**14**:361-8.
- 12 Dembinski J, Behrendt D, Martini R, et al. Modulation of pro- and anti-inflammatory cytokine production in very preterm infants. *Cytokine* 2003;**21**:200-6.
- 13 Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN- $\gamma$  gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN- $\gamma$  production. *Hum Immunol* 2000;**61**:863-6.
- 14 Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? *Liver Transpl* 2003;**9**:170-81.
- 15 Huang D, Cancilla MR, Morahan G. Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit. *Genes Immun* 2000;**1**:515-20.
- 16 Morahan G, Huang D, Wu M, et al. Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children [correction appears in *Lancet* 2002;**360**:1892]. *Lancet* 2002;**360**:455-9.
- 17 Morahan G, Boutlis CS, Huang D, et al. A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. *Genes Immun* 2002;**3**:414-18.
- 18 Heep A, Schueller AC, Kattner E, et al. Association of two tumour necrosis factor gene polymorphisms with the incidence of severe intraventricular haemorrhage in preterm infants. *J Med Genet* 2005;**42**:604-8.

- 19 **Anells MF**, Hart PH, Mullighan CG, *et al.* Interleukins-1, -4, -6, -10, tumor necrosis factor, transforming growth factor-beta, FAS, and mannose-binding protein C gene polymorphisms in Australian women: risk of preterm birth. *Am J Obstet Gynecol* 2004;**191**:2056-67.
- 20 **Amory JH**, Adams KM, Lin MT, *et al.* Adverse outcomes after preterm labor are associated with tumor necrosis factor-alpha polymorphism-863, but not-308, in mother-infant pairs. *Am J Obstet Gynecol* 2004;**191**:1362-7.
- 21 **Kazzi SN**, Kim UO, Quasney MW, *et al.* Polymorphism of tumor necrosis factor-alpha and risk and severity of bronchopulmonary dysplasia among very low birth weight infants. *Pediatrics* 2004;**114**:e243-8.
- 22 **Bokodi G**, Treszl A, Derzbach L, *et al.* The association of the carrier state of the tumor necrosis factor-alpha (TNFalpha)-308A allele with the duration of oxygen supplementation in preterm neonates. *Eur Cytokine Netw* 2005;**16**:78-80.
- 23 **Khoo SK**, Hayden CM, Roberts M, *et al.* Associations of the IL12B promoter polymorphism in longitudinal data from asthmatic patients 7 to 42 years of age. *J Allergy Clin Immunol* 2004;**113**:475-81.
- 24 **Jobe AH**, Bancalari E. Bronchopulmonary dysplasia. NICHD-NHLBI-ORD Workshop. *Am J Respir Crit Care Med* 2001;**163**:1723-9.
- 25 **Tausch HW**, Ballard RA, Gleason CA. *Avery's diseases of the newborn*. Philadelphia: Elsevier, 2005.
- 26 **Treszl A**, Kocsis I, Szathmari M, *et al.* Genetic variants of TNF- $\alpha$ , IL-1beta, IL-4 receptor  $\alpha$ -chain, IL-6 and IL-10 genes are not risk factors for sepsis in low-birth-weight infants. *Biol Neonate* 2003;**83**:241-5.
- 27 **Jobe AH**, Ikegami M. Mechanisms initiating lung injury in the preterm. *Early Hum Dev* 1998;**53**:81-94.
- 28 **Morahan G**, Huang D, Ymer SJ, *et al.* Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele [correction appears in *Nat Genet* 2001;**27**:346]. *Nat Genet* 2001;**27**:218-21.
- 29 **Prigoshin N**, Tambutti M, Larriba J, *et al.* Cytokine gene polymorphisms in recurrent pregnancy loss of unknown cause. *Am J Reprod Immunol* 2004;**52**:36-41.
- 30 **Daher S**, de Arruda G, Denardi K, Blotta MH, *et al.* Cytokines in recurrent pregnancy loss. *J Reprod Immunol* 2004;**62**:151-7.
- 31 **Bont L**, Heijnen CJ, Kavelaars A, *et al.* Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J Infect Dis* 2001;**184**:355-8.
- 32 **Suzuki N**, Chen NJ, Millar DG, *et al.* IL-1 receptor-associated kinase 4 is essential for IL-18-mediated NK and T<sub>H1</sub> cell responses. *J Immunol* 2003;**170**:4031-5.
- 33 **Ng PC**, Li K, Wong RP, *et al.* Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. *Arch Dis Child Fetal Neonatal Ed* 2003;**88**:F209-13.
- 34 **Hodge G**, Hodge S, Haslam R, *et al.* Rapid simultaneous measurement of multiple cytokines using 100 microl sample volumes—association with neonatal sepsis. *Clin Exp Immunol* 2004;**137**:402-7.
- 35 **Fraser J**, Walls M, McGuire W. Respiratory complications of preterm birth. *BMJ* 2004;**329**:962-5.
- 36 **Hitti J**, Krohn MA, Patton DL, *et al.* Amniotic fluid tumor necrosis factor-alpha and the risk of respiratory distress syndrome among preterm infants. *Am J Obstet Gynecol* 1997;**177**:50-6.

### Clinical Evidence—Call for contributors

*Clinical Evidence* is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

#### Areas for which we are currently seeking contributors:

- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit [www.clinicalevidence.com/ceweb/contribute/index.jsp](http://www.clinicalevidence.com/ceweb/contribute/index.jsp)

However, we are always looking for others, so do not let this list discourage you.

#### Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to [CECommissioning@bmjgroup.com](mailto:CECommissioning@bmjgroup.com).

### Call for peer reviewers

*Clinical Evidence* also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and out turnaround time for each review is ideally 10-14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at [www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp](http://www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp)